Palbociclib has successfully induced cellular senescence in melanoma, liposarcoma, gastric cancer, and hepatocellular carcinoma by inhibiting the mammalian target of rapamycin (mTOR) signaling pathway [84,85]. Here, MTOR is linked to liposarcoma.